Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Grossmann

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
Blood Cancer Journal|September 4, 2012
Molecular analysis of RAS-RAF tyrosine-kinase signaling pathway alterations in patients with plasma cell myelomaV Grossmann, U Bacher, V Artusi, et al.
Leukemia|July 21, 2012
GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosisA Fasan, C Eder, C Haferlach, et al.
Leukemia|September 10, 2011
The NPM1 wild-type OCI-AML2 and the NPM1-mutated OCI-AML3 cell lines carry DNMT3A mutationsE Tiacci, A Spanhol-Rosseto, M P Martelli, et al.
Leukemia|March 29, 2013
High incidence of RAS signalling pathway mutations in MLL-rearranged acute myeloid leukemiaV Grossmann, S Schnittger, F Poetzinger, et al.
Leukemia|January 22, 2011
Targeted next-generation sequencing detects point mutations, insertions, deletions and balanced chromosomal rearrangements as well as identifies novel leukemia-specific fusion genes in a single procedureV Grossmann, A Kohlmann, H-U Klein, et al.
Leukemia|August 21, 2013
Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant diseaseA Kohlmann, N Nadarajah, T Alpermann, et al.
Blood Cancer Journal|September 4, 2012
Expression of CEBPA is reduced in RUNX1-mutated acute myeloid leukemiaV Grossmann, U Bacher, A Kohlmann, et al.
Leukemia|October 12, 2013
SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patientsS Jeromin, S Weissmann, C Haferlach, et al.
Leukemia|March 23, 2013
Landmark analysis of DNMT3A mutations in hematological malignanciesA Roller, V Grossmann, U Bacher, et al.
Leukemia|January 29, 2011
A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of casesV Grossmann, A Kohlmann, M Zenger, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
Blood Cancer Journal|September 4, 2012
Molecular analysis of RAS-RAF tyrosine-kinase signaling pathway alterations in patients with plasma cell myelomaV Grossmann, U Bacher, V Artusi, et al.
Leukemia|July 21, 2012
GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosisA Fasan, C Eder, C Haferlach, et al.
Leukemia|September 10, 2011
The NPM1 wild-type OCI-AML2 and the NPM1-mutated OCI-AML3 cell lines carry DNMT3A mutationsE Tiacci, A Spanhol-Rosseto, M P Martelli, et al.
Leukemia|March 29, 2013
High incidence of RAS signalling pathway mutations in MLL-rearranged acute myeloid leukemiaV Grossmann, S Schnittger, F Poetzinger, et al.
Leukemia|January 22, 2011
Targeted next-generation sequencing detects point mutations, insertions, deletions and balanced chromosomal rearrangements as well as identifies novel leukemia-specific fusion genes in a single procedureV Grossmann, A Kohlmann, H-U Klein, et al.
Leukemia|August 21, 2013
Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant diseaseA Kohlmann, N Nadarajah, T Alpermann, et al.
Blood Cancer Journal|September 4, 2012
Expression of CEBPA is reduced in RUNX1-mutated acute myeloid leukemiaV Grossmann, U Bacher, A Kohlmann, et al.
Leukemia|October 12, 2013
SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patientsS Jeromin, S Weissmann, C Haferlach, et al.
Leukemia|March 23, 2013
Landmark analysis of DNMT3A mutations in hematological malignanciesA Roller, V Grossmann, U Bacher, et al.
Leukemia|January 29, 2011
A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of casesV Grossmann, A Kohlmann, M Zenger, et al.
Pageof 6